# Xcovery

Source: https://onco.cc/companies/xcovery/  
OnCo record `xcovery` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first.

## Summary

Xcovery Holdings, based in Palm Beach Gardens, Florida, developed ensartinib (Ensacove), a second-generation ALK inhibitor. Its Chinese partner Betta Pharmaceuticals won approval there in 2020, and the FDA approved ensartinib in December 2024 for ALK-positive locally advanced or metastatic non-small-cell lung cancer in patients not previously treated with an ALK inhibitor, on the eXalt3 trial against crizotinib. Company facts are from the official website and FDA approval records.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Xcovery Holdings, Inc.
- Tags: fda-oce-applicant
- HQ: Palm Beach Gardens, FL
- Type: biotech
- Website: https://www.xcovery.com/

## Sources

- Official website: https://www.xcovery.com/
- FDA: oncology and hematologic malignancies approval notifications: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Ensartinib](https://onco.cc/drugs/ensartinib/)
- trials: [BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct05393466/), [eXalt3](https://onco.cc/trials/nct02767804/)

---
JSON: https://onco.cc/api/v1/entities/xcovery.json